Lantern Pharma Inc. Net Income (Loss) Attributable to Noncontrolling Interest
Lantern Pharma Inc. (LTRN) reported Net Income (Loss) Attributable to Noncontrolling Interest of $4.12 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-03.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2022-05-03
- Lantern Pharma Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2022-03-31 was $4.12M, a 68.11% increase year-over-year.
- Lantern Pharma Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2021-12-31 was $3.54M, a 22.24% increase year-over-year.
- Lantern Pharma Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2021-09-30 was $4.05M, a 138.33% increase year-over-year.
- Lantern Pharma Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2021-06-30 was $2.32M.
- Lantern Pharma Inc. net income (loss) attributable to noncontrolling interest for fiscal 2021 was $12.36M, a 109.26% increase from fiscal 2020.
- Lantern Pharma Inc. net income (loss) attributable to noncontrolling interest for fiscal 2020 was $5.91M.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2022-03-31 | $4.12M 10-Q · filed 2022-05-03 | $7.66M derived: sum of 2 quarters · filed 2022-05-03 | $11.72M derived: sum of 3 quarters · filed 2022-05-03 | $14.03M derived: sum of 4 quarters · filed 2022-05-03 |
| 2021-12-31 | $3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $7.59M derived: sum of 2 quarters · filed 2022-03-10 | $9.91M derived: sum of 3 quarters · filed 2022-03-10 | $12.36M 10-K · filed 2022-03-10 |
| 2021-09-30 | $4.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $6.37M derived: sum of 2 quarters · filed 2021-11-01 | $8.82M 10-Q · filed 2021-11-01 | $11.72M derived: sum of 4 quarters · filed 2022-05-03 |
| 2021-06-30 | $2.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $4.77M 10-Q · filed 2021-07-29 | $7.67M derived: sum of 3 quarters · filed 2022-05-03 | $9.37M derived: sum of 4 quarters · filed 2022-05-03 |
| 2021-03-31 | $2.45M 10-Q · filed 2022-05-03 | $5.35M derived: sum of 2 quarters · filed 2022-05-03 | $7.05M derived: sum of 3 quarters · filed 2022-05-03 | |
| 2020-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $4.60M derived: sum of 2 quarters · filed 2022-03-10 | $5.91M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $3.01M 10-Q · filed 2021-11-01 | ||
| 2020-06-30 | $1.31M 10-Q · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |